The Journal of Clinical Pharmacology · 1999 · 25 citations · 10 references
PharmacyClinical PharmacokineticsPharmacologyCompartmental ModelingDrug ClearanceRenal PharmacokineticsPharmacokinetics In Renal ImpairmentRenal ClearanceRenal DiseaseRenal Drug DistributionRenal ImpairmentRenal PharmacologyBolus-plus-infusion RegimensChronic Renal InsufficiencyClearance Based PharmacokineticsPharmacokinetics In Kidney DiseaseSerious Adverse Events
The pharmacokinetics of intravenously administered recombinant human interleukin-10 (rHuIL-10) were evaluated in 18 subjects with creatinine clearances (Clcr) between 2.7 and 116.7 mL/min/1.73 m2. Serum samples for rHuIL-10 were obtained over a 48-hour period after a single 25 micrograms/kg i.v. bolus infusion. AUC, total body clearance (Clp), and steady-state volume of distribution (Vdss) were derived by compartmental methods. Analysis of serum concentrations showed statistically significant group differences for log-transformed AUC and original scale Clp (p < 0.01). The AUC and effective half-life increased, while the mean Clp of rHuIL-10 decreased as renal function declined. A linear relationship between AUC and Clcr as well as Clp and Clcr demonstrates that the disposition of rHuIL-10 is altered in subjects with renal insufficiency. No serious adverse events were noted.
10
IL-10 inhibits cytokine production by activated macrophages
David Fiorentino, Albert Zlotnik, Tim R. Mosmann et al. · The Journal of Immunology · 1991 · 2.9K citations · Full text
René de Waal Malefyt, John B.A.G. Haanen, Hergen Spits et al. · The Journal of Experimental Medicine · 1991 · 1.9K citations · Full text
Paulo Vieira, René de Waal Malefyt, M N Dang et al. · Proceedings of the National Academy of Sciences · 1991 · 752 citations
Life Sciences, Genetics, Immunology +10